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OBJECTIVE: Women who become pregnant during the
conduct of biomedical human immunodeficiency virus
prevention trials are taken off the study product for
safety reasons. High pregnancy rates can compromise
statistical integrity in these trials. The comprehensive
contraceptive curriculum developed for the Centre for
the AIDS Programme of Research in South Africa
(CAPRISA) 004 trial was evaluated for its ability to en-
hance contraceptive uptake, reduce pregnancy rates, and
preserve statistical integrity.
METHODS: Contraceptive- and pregnancy-related eligi-
bility criteria were specified in the protocol. We enrolled
women who opted for a nonbarrier method of contra-
ceptive and provided hormonal contraceptives onsite at
no cost. At each monthly study visit, we provided preg-
nancy prevention counseling and performed pregnancy
testing. Study product was withheld on pregnancy diag-
nosis, but women continued with monthly follow-up.
RESULTS: Contraceptive use was high throughout the
study with 100% uptake at baseline and 94.71% use after
a mean of 18 months follow-up at exit. Injectable pro-
gestins, particularly medroxyprogesterone acetate, re-
mained the preferred choice of contraceptive. After 30
months of follow-up, 54 pregnancies were reported out
of 889 participants, giving a pregnancy incidence rate of
3.95 per 100 woman-years (95% confidence interval
2.96–5.17). Of all pregnancies, two thirds (64.81%) re-
sulted in a full-term live birth, whereas 18.52% and
11.11% pregnancies culminated as miscarriage and ter-
minated pregnancies, respectively. There were no con-
genital anomalies in the early neonatal period. Pregnan-
cies resulted in 1.56% of woman-years of study follow-up
lost as a result of temporary product withdrawal.
CONCLUSION: The CAPRISA 004 contraceptive curric-
ulum was an effective strategy for maintaining low preg-
nancy rates, thereby minimizing product withdrawal and
loss of follow-up time.
(Obstet Gynecol 2011;118:895–904)
DOI: 10.1097/AOG.0b013e31822be512
LEVEL OF EVIDENCE: III
In 2009, there were an estimated 33.3 million hu-man immunodeficiency virus (HIV)-infected peo-
ple globally.1 A distinctive feature of this epidemic in
the 21st century is its increasing burden on young
women. In sub-Saharan Africa, women aged 15–24
years are as much as eight times more likely to be
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HIV-positive than men of the same age.2 Although
condoms are an effective HIV prevention strategy,
many women are unable to successfully negotiate
their use with their male partners, making an HIV
prevention method that women can initiate and con-
trol a priority. Since 1990, various women-initiated
candidate biomedical microbicides have been tested
in effectiveness trials3 to assess their effect on prevent-
ing HIV infection, and several more trials are under-
way or planned.4
All biomedical microbicide trials, irrespective of
the product being investigated, share common chal-
lenges. Because these trials enroll mostly women
within the reproductive age group, one of the
greatest challenges has been the high pregnancy
rates, ranging from 21 to 76 per 100 person-
years.5–10 Women who become pregnant during
clinical trials of experimental drugs must be taken
off the product for safety reasons. Frequent and
prolonged product withdrawal can compromise
statistical integrity in these trials.6
Although all efforts are made to limit exposure to
experimental drugs during pregnancy, some women
may use the study product during the first weeks of
pregnancy. Therefore, it is important to monitor the
safety of the study product on pregnancy rates and
outcomes. Although little is known about the safety of
tenofovir gel when used during pregnancy, the oral
formulation, Tenofovir disoproxil fumarate, which
has been widely used by HIV-infected individuals for
treatment, is designated as a pregnancy category B
drug in the United States and has a reassuring terato-
genic profile. Congenital anomaly rates at 2.72 per
100 live births are comparable with those in the
Centers for Disease Control and Prevention’s popu-
lation-based birth defects surveillance system in the
United States and to the rates of other antiretroviral
drugs in the Antiretroviral Pregnancy Registry.11
With these challenges in mind, we hypothesized
that an intensive comprehensive contraceptive curric-
ulum is an effective strategy for enhancing contracep-
tive uptake, reducing pregnancy rates, minimizing
inadvertent in utero drug exposure, and thereby
maintaining statistical integrity and fetal safety in
biomedical HIV prevention trials. We provide an
analysis of contraceptive choices, pregnancy rates,
and outcomes from the Centre for the AIDS Pro-
gramme of Research in South Africa (CAPRISA) 004
tenofovir gel trial.
MATERIALS AND METHODS
CAPRISA 004, a phase IIb placebo-controlled, dou-
ble-blind randomized clinical trial, was conducted to
assess safety and effectiveness of 1% vaginal tenofovir
gel to reduce HIV acquisition in women at one rural
(Vulindlela) and one urban (eThekwini) clinic in
South Africa.12 A total of 889 nonpregnant HIV-
uninfected women between the ages of 18 and 40
years were eligibly enrolled and followed up for an
average of 18 months (range 12–30 months), 611 from
the rural site and 278 from the urban site. The goal
was to enroll up to 1,250 women over approximately
18 months and to continue follow-up until 92 incident
infections were observed. This number of events was
expected to provide 90% power to detect a 50% effect
(using a two-sided 0.05 significance level test).
Participants were accrued over 19 months from May
2007 to January 2009. Women were randomly as-
signed in equal proportions to one of two study arms:
tenofovir gel and placebo gel within 30 days of the
screening visit. To facilitate blinding, each participant
was randomly assigned within one of six different
groups (designated by an alphanumeric variable, eg,
A, B, C, D, E, and F) in a 1:1:1:1:1:1 allocation ratio.
Three groups corresponded to the placebo and three
to tenofovir gel. This analysis includes all women
enrolled into CAPRISA 004 and included in the
intention-to-treat analysis.
The main outcome of this analysis was pregnancy
incidence rates. Other outcomes included contracep-
tive uptake and adherence, pregnancy outcomes, and
time off study product. We developed tools and aids
to support the trial’s comprehensive contraceptive
curriculum, which were used from the screening visit
until study termination. We used these tools to train
clinical staff on contraceptive counseling for the trial
participants and to guide clinical staff with regard to
all pregnancy-related procedures including study
product withdrawal and resumption.
Clinical staff conducted urine pregnancy tests at
screening and pregnant women were excluded. As
part of eligibility criteria, we assessed a participant’s
contraceptive needs and pregnancy intentions over
the study duration. Only women who were not plan-
ning to become pregnant sometime over the duration
of the study and agreed to use a nonbarrier method of
contraception for the duration of the study were
offered enrollment into the study. Other nonpreg-
nancy or contraceptive-related exclusions are pro-
vided elsewhere.13 We repeated pregnancy tests at
enrollment if more than 21 days had lapsed between
the screening and enrollment visits.
We provided hormonal contraceptives onsite at
no cost, including progesterone-containing injectables
(depot-medroxyprogesterone acetate and norethis-
terone enanthate and combined oral contraceptives).
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Women were referred to the nearest family planning
institution per referral guidelines issued by the South
African Department of Health if they opted for a
nonhormonal method such as an intrauterine device
or tubal ligation. Contraceptive choice was recorded
on a family planning card and an individual contra-
ceptive history log that was updated at each study visit
and was retained in the participant binder. Barrier
methods including both male and female condoms
were provided at each study visit but were promoted
principally as an HIV risk reduction method.
Trained clinical study staff provided individual
contraceptive counseling as part of routine monthly
follow-up procedure. Contraceptive counseling was
individualized and tailored according to each wom-
an’s needs. We used a contraceptive log to indirectly
assess compliance with a method. To enhance con-
tinual supply, participants’ contraceptive visits were
scheduled to coincide with their regular monthly
study visits whenever possible. Participants who
chose to receive their contraception from a govern-
ment family planning clinic were required to bring
their signed Department of Health family planning
cards to each study visit for study data collection on
use of contraceptive methods.
Urine pregnancy testing was conducted monthly.
Participants testing positive for pregnancy continued
with monthly follow-up visits but study product was
temporarily withheld. A woman continued to have
monthly pregnancy tests for the first 3 months of
pregnancy to exclude unrecognized early preclinical
pregnancy loss. Blood -human chorionic gonadotro-
pin quantification was done to confirm ambiguous
urine results. Product was resumed after a live birth or
once the chemical tests (urine, blood, or both) re-
verted to negative after pregnancy end.
On pregnancy cessation, the clinical staff col-





Did not return on time: 142
Did not meet criteria for “sexually active”: 132
Pregnant or planning pregnancy: 51
Participating in other research: 37
Refused participation: 33
Not on reliable contraception: 26
Allergic to latex: 24
Planning to relocate away from study area: 23
Medical condition precluding enrollment: 23
Unable to attend study visits: 19
























Terminations of pregnancy: 2
Pregnancy outcomes at
Vulindlela: n=21*
Term deliveries: 14 
(2 neonatal deaths)
Miscarriages: 2
Terminations of pregnancy: 2






Termination of pregnancy: 1
Excluded: n=196
Ineligible, based on pre-enrollment criteria: 194
No post-randomization follow-up or HIV test: 2
Fig. 1. Screening, enrollment, and pregnancy outcomes after 30 months of follow-up in the Centre for the AIDS Programme
of Research in South Africa (CAPRISA) 004 tenofovir gel trial by study arm and site. *There were 55 pregnancy outcomes
from 54 pregnancies. One woman was pregnant twice, and one gave birth to twins.
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mented pregnancy outcomes. Pregnant women pre-
sented their newborns once in the early postpartum
period to the study clinician for assessment of abnor-
malities, if any. Case reports of each pregnancy were
discussed during the Protocol Safety Review Team
meetings. The Protocol Safety Review Team com-
prised the principal investigators, the study obstetri-
cian, the study and site clinicians, project directors,
and an independent clinician. This team met regu-
larly, initially every 3 months then every 2 months, to
review blinded safety information from the study.
The trial (NCT00441298) was reviewed and
approved by the University of KwaZulu-Natal’s
Biomedical Research Ethics Committee (BREC ref.
E 111/06), the South Africa Medicines Control
Council (MCC ref. 20060835), and Family Health
International’s Protection of Human Subjects Com-
mittee (PHSC ref. 9946). Before enrollment into the
study, written informed consent was obtained from
each participant.
Outcome measures of this analysis included con-
traceptive uptake and use patterns, pregnancy rates
and pregnancy outcomes, and time off study product.
Contraception and pregnancy data were entered onto
standardized case report forms at the study sites and
were faxed into the CAPRISA Data Management
Centre using the DataFax system. Data on contracep-
tive method at each visit starting from screening,
pregnancy diagnosis date, date of study product with-
drawal and resumption, and pregnancy outcomes
Table 1. Baseline Demographic Characteristics and Sexual Behavior by Study Arm
Variable All Tenofovir Arm Placebo Arm P
Site .77
eThekwini 278 137 (30.8) 141 (31.8)
Vulindlela 611 308 (69.2) 303 (68.2)
Age (y) 23.88  5.11 24.17  5.26 23.59  4.94 .13
Marital status
Married 50 26 (5.84) 24 (5.41) .92
Other 56 29 (6.52) 27 (6.08)
Stable 783 390 (87.64) 393 (88.51)
Highest education
No schooling 4 2 (0.45) 2 (0.45) .30
Primary schooling complete 10 6 (1.35) 4 (0.90)
Primary school not complete 27 19 (4.27) 8 (1.80)
High school complete 301 150 (33.71) 151 (34.01)
High school not complete 483 238 (53.48) 245 (55.18)
Tertiary education complete 18 11 (2.47) 7 (1.58)
Tertiary education not complete 46 19 (4.27) 27 (6.08)
Number of children
0 197 90 (20.23) 107 (24.10) .42
1 470 238 (53.48) 232 (52.25)
2 147 73 (16.40) 74 (16.67)
3 50 30 (6.74) 20 (4.51)
4 or more 25 14 (3.15) 11 (2.48)
Sex acts in past 30 d
0 22 11 (2.47) 11 (2.48) .13
1–5 360 186 (41.80) 174 (39.19)
6–10 299 134 (30.11) 165 (37.16)
11 or more 208 114 (25.62) 94 (21.17)
Casual partner in past 30 d
0 826 412 (92.58) 414 (93.24) .96
1 43 23 (5.17) 20 (4.51)
2 or more 20 10 (2.25) 10 (2.25)
Condom use during sex
Always 259 128 (28.76) 131 (29.51) .81
Occasionally 630 317 (71.24) 313 (70.50)
Contraception
Injectable 730 359 (80.67) 371 (83.56) .29
Oral 138 73 (16.40) 65 (14.64)
Tubal ligation 20 13 (2.92) 7 (1.58)
Hysterectomy 1 0 (0.0) 1 (0.23)
Data are n (%) or meanstandard deviation unless otherwise specified.
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were captured and entered into the study database.
Pregnancy outcomes documented included miscar-
riages, terminations of pregnancy, stillbirths, preterm
live births with and without congenital anomalies, and
full-term live births with and without congenital
anomalies. Adverse maternal outcomes were also
documented as adverse events.
For the first part of the analysis, contraceptive
method groups were defined according to baseline
method used and did not take into account method
switching, discontinuation, missed visits, or contra-
ceptives obtained from other external sources. We
calculated incidence rates of pregnancy per 100 woman-
years of observation for each contraceptive category
considering method used up to the time of index
pregnancy, thereby excluding pregnancy periods.
This latter part of the analysis considered method
switching, discontinuation, and missed study visits.
Estimated date of pregnancy, in days, was calculated
as the midpoint between the date of the first positive
pregnancy test and the date of the previous negative
pregnancy test. For women who had a pregnancy
outcome with no pregnancy testing or women with
several missed visits before a positive pregnancy test,
the pregnancy start date was defined as 14 days after
the last normal menstrual period. For women who did
not become pregnant during the study, the censoring
date was the last date with a negative pregnancy test
on or before study termination date. Duration of time
on study (in months) was calculated from randomiza-
tion to estimated date of pregnancy or date of with-
drawal or termination from study, whichever oc-
curred first. In women with two pregnancy diagnoses
during study follow-up period, only the first preg-
nancy was included in Kaplan-Meier analysis. Uni-
variable and multivariable Cox proportional hazards
analysis was used to examine baseline factors associ-
ated with incident pregnancy.
Statistical analysis was done using SAS 9.1.3. All
statistical tests were two-sided and done at 5% level of
significance. Fisher’s exact or chi-square tests were
used for testing associations between categorical data.
A Poisson distribution was assumed for 95% confidence
intervals (CIs) of pregnancy rates14 and incidence rate
ratios. Unpaired t test and Wilcoxon rank sum two-
sample tests were performed where appropriate.
RESULTS
Of 2,160 women screened, 51 were screened out for
pregnancy-related indications: 36 were already preg-
nant and 15 were planning to become pregnant
sometime during the study duration. Twenty-six
women were not on an eligible method of contracep-
tion. Nine hundred ninety-eight women were ex-
cluded for other nonpregnancy- or contraceptive-
related indications. After randomization, 196 women
were excluded from the analysis for ineligibility based
on pre-enrollment criteria.12 A total of 889 nonpreg-
Table 2. Contraceptive Method Uptake at Baseline and Use at Study Exit by Site
Vulindlela (n  611) eThekwini (n  278) Total (n  889)
Baseline Exit Baseline Exit Baseline Exit
DMPA 442 (72.34) 435 (71.19) 140 (50.36) 119 (42.81) 582 (65.47) 554 (62.32)
NET-EN 66 (10.80) 73 (11.95) 82 (29.50) 76 (27.34) 148 (16.65) 149 (16.76)
COC 89 (14.57) 63 (10.31) 49 (17.63) 55 (19.78) 138 (15.52) 118 (13.27)
Tubal ligation 13 (2.13) 13 (2.13) 7 (2.52) 7 (2.52) 20 (2.25) 20 (2.25)
Hysterectomy 1 (0.16) 1 (0.22) 0 (0.0) 0 (0.0) 1 (0.11) 1 (0.11)
No method 0 (0.0) 26 (4.26) 0 (0.0) 21 (7.55) 0 (0.0) 47 (5.29)
All methods 611 (100.0) 585 (95.74) 278 (100.0) 257 (92.45) 889 (100.0) 842 (94.71)
DMPA, depot medroxyprogesterone acetate; NET-EN, norethisterone enanthate; COC, combined oral contraceptive.
Data are n (%).
Table 3. Pregnancy Rates by Study Arm and Study Site
Variable
Vulindlela (n  34) eThekwini (n  19)
Total (n  53)Tenofovir Placebo Tenofovir Placebo
No. of pregnancies 14 20 8 11 53
Pregnancy incidence per
100 woman-years
2.90 4.30 4.07 5.62 3.95
Incidence rate ratio 0.67 0.72 0.69
Confidence interval (P) .31–1.40 (.25) .25–1.98 (.49) .38–1.23 (.18)
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nant women were eligibly enrolled in the CAPRISA
004 trial and were included in this analysis (Fig. 1).
Women from the urban site were older, more
likely to have a stable partner, and had a lower monthly
income. Women at the rural site reported fewer lifetime
sexual partners (2.1 compared with 6.0; P.001) and
had younger partner(s) in the 30 days before enrollment
(26.4 compared with 39.6; P.001).13 The mean age of
the participants was 23.9 years. Three fourths of the
women were multiparous, almost all were in stable
relationships, few reported having a casual partner in the
30 days before enrollment, and 71% reported inconsis-
tent condom use (Table 1).
All women were using a nonbarrier method of
contraception at the time of enrollment into the study;
730 (82.12%) chose an injectable form of contracep-
tive, 138 (15.52%) chose combined oral contracep-
tives, and 21 (2.36) had undergone female sterilization
(20 tubal ligations and one hysterectomy) (Table 2).
Depot-medroxyprogesterone acetate was a most pop-
ular injectable method, used by more women than
norethisterone enanthate throughout the follow-up
period. Overall, method switching was uncommon
and contraceptive use remained high throughout the
study. At study exit, 47 (5.29%) of participants re-
ported not using any contraceptive method.
At the end of 30 months of study follow-up, the
overall pregnancy incidence rate was 3.95 per 100
woman-years (95% CI 2.96–5.17), somewhat higher
in the urban than the rural cohorts (incidence rate
ratio 0.75, 95% CI 0.41–1.37, z-test P.30). Although
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Fig. 2. Kaplan-Meier survival curve for pregnancy in the
Centre for the AIDS Programme of Research in South Africa
(CAPRISA) 004 trial.
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Gynecol 2011.










(n  21) Total
Age group (y)
18–24 398 (68.38) 105 (70.95) 74 (53.62) 2 (9.52) 579
25–29 112 (19.24) 29 (19.59) 32 (23.19) 4 (19.05) 177
30–34 44 (7.56) 10 (6.76) 22 (15.94) 9 (42.86) 85
35 or older 28 (4.81) 4 (2.70) 10 (7.25) 6 (28.57) 48
Median (IQR) 22 (20–26) 22 (20–25) 24 (20–29) 33 (29–35)
Parity
0 91 (15.64) 51 (34.46) 55 (39.86) 0 (0.0) 197
1 349 (59.97) 71 (47.97) 50 (36.23) 0 (0.0) 470
2 100 (17.18) 20 (13.51) 23 (16.67) 4 (19.05) 147
3 29 (4.98) 3 (2.03) 8 (5.80) 10 (47.62) 50
4 or more 13 (2.23) 3 (2.03) 2 (1.45) 7 (33.33) 25
Pregnant
Negative 570 (97.94) 145 (97.97) 100 (72.46) 21 (100.0) 836
Positive 12 (2.06) 3 (2.03) 38 (27.54) 0 (0.0) 53
Pregnancy incidence rate per
100 woman-years (95% CI)
1.34 (0.69–2.35) 1.37 (0.28–3.99) 19.73 (13.96–27.08)
Pregnancy rate*
Pregnancy incidence rate per
100 woman-years (95% CI)
0.46 (0.13–1.18) 1.75 (0.48–4.49) 11.47 (7.27–17.22)
DMPA, depot-medroxyprogesterone acetate; NET-EN, norethisterone enanthate; COC, combined oral contraceptive; IQR, interquartile
range; CI, confidence interval.
Data are n (%) unless otherwise specified.
* At the time of index pregnancy accounting for method switching.
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slightly lower in the tenofovir gel arm than the
placebo arm (z-test P.18; Table 3). Pregnancy rates
remained somewhat static at approximately four per
100 woman-years from beginning through to study
completion (Fig. 2).
By study end, 54 pregnancies were observed
among 53 women who had 55 outcomes between
them (Fig. 1). One participant was pregnant twice and
another had a twin pregnancy. Participants who be-
came pregnant had similar baseline characteristics as
those who did not become pregnant except for level
of education: 97.2% had a high school education
compared with 88.2% in the nonpregnant group.
Among the 54 pregnancies, 10 (18.52%) resulted
in miscarriages (including four probable chemical and
spurious pregnancies), six (11.11%) were terminated
(including one noninvasive mole), 35 (64.81%) re-
sulted in full-term live deliveries (two early neonatal
deaths), and four (7.41%) resulted in preterm deliver-
ies (one early neonatal death) (Fig. 1). All three
children with diagnosed fetal distress syndrome were
in the placebo arm. There were no stillbirths. All early
neonatal deaths were in the placebo arm. There were
no congenital abnormalities observed.
Of the 39 viable pregnancies, three delivered by
cesarean delivery (two in the tenofovir arm and one in
the placebo arm), one had postpartum hemorrhage,
and one had premature rupture of membranes. The
latter two were allocated to the tenofovir gel arm.
As expected, pregnancy rates based on category
of contraceptive method used at baseline were 19
times higher among combined oral contraceptive
users than among injectable contraceptive users with
no distinct differences between depot-medroxypro-
gesterone acetate and norethisterone enanthate users
(Table 4). However, taking method switching and
discontinuation into consideration, the pregnancy
rates were lowest among depot-medroxyprogesterone
acetate users (0.46 per 100 woman years, 95% CI
0.13–1.18) followed by norethisterone enanthate (1.75
per 100 woman years, 95% CI 0.48–4.49) and com-
bined oral contraceptive (11.47 per 100 woman years,
95% CI 7.27–17.22) users.
Pregnancies occurred in women who either missed
study visits, thus discontinuing method use (22 of 53
[41.51%]), or did not miss study visits but were on
combined oral contraceptives (19 of 53 [35.85%]), or
switched contraceptive methods (12 of 53 [22.64%])
(Fig. 3).
Three women who became pregnant also became
HIV-infected during the study, all in the placebo arm.
Two of these pregnancies were diagnosed before HIV
seroconversion.
Method of contraception was the only baseline
factor that was significantly associated with pregnancy
in both the univariable and multivariable propor-
tional hazard models. The adjusted hazard ratio for
combined oral contraceptive use was 15.91 (95% CI
8.03–31.52, P.001; Table 5). Inconsistent condom
use in the past 30 days was also a significant predictor
of pregnancy with a hazard ratio of 2.05 (1.04–4.04)
in the multivariable model.
Total person-time of observation was 1,340.7
woman-years. Time off product as a result of preg-
nancies was 20.9 woman-years (1.56% of total person-
time), mostly attributable to the full-term births.
The median time between date of last product use
and pregnancy detection was 14 days (range 0–92
days).
DISCUSSION
The high contraceptive use throughout follow-up in
this trial resulted in a low overall pregnancy rate of
3.95 per 100 woman-years. This pregnancy rate was
lower compared with 17.7 per 100 woman-years that
was observed in the CAPRISA 050/051 microbicide
preparedness study, a study conducted without the
implementation of the contraceptive curriculum.15
The observed pregnancy rate in the CAPRISA 004
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Fig. 3. Clinic attendance and contraceptive use patterns
among women who became pregnant (n53) in the Centre
for the AIDS Programme of Research in South Africa
(CAPRISA) 004 trial. DMPA, depot medroxyprogesterone
acetate.
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even after procedures were revised to dispense con-
traceptives at the study sites.16 The low pregnancy rate
observed in the CAPRISA 004 trial suggests that the
contraceptive curriculum was effective in reducing
pregnancy rates. Onsite method provision and study
visits synchronized with injectable administration fur-
ther enhanced compliance with the method. Most
importantly, CAPRISA 004 was the first trial to
include an eligibility criterion requiring effective con-
traceptive initiation and provide effective methods
onsite. Future biomedical prevention trials should
consider including a comprehensive contraception
strategy to effectively reduce pregnancy rates.
Although not statistically significant, pregnancy
incidence rates were higher in the tenofovir gel
arm. Although tenofovir gel is not known to reduce
probability of conception, there needs to be vigi-
lance in evaluating this association in future teno-
fovir trials.
Pregnancies that did occur in the CAPRISA 004
trial were mainly among combined oral contraceptive
users. The pregnancy rate was more than 10-fold
higher in combined oral contraceptive users than
depot-medroxyprogesterone acetate users, and com-
bined oral contraceptive use was the most important
predictor of pregnancy in this trial, a finding consis-
tent with findings in the HPTN 039 study.17 Inadver-
tent pregnancies in pill users are not uncommon and
often involve pill-taking errors, although many factors
may contribute to “pill failure.”18 Data from the
United States indicate that pregnancy rates within the
first year of perfect method use are the same for
combined oral contraceptives and depot-medroxy-
progesterone acetate at 0.3%. However, by 12
months, the pregnancy rate with typical use for
combined oral contraceptives is 8% compared with
3% for depot-medroxyprogesterone acetate.19 The
combined oral contraceptive pregnancy rate was
higher still in this trial.
Pregnancies occurred with higher frequency
among women who missed one or more study visits
or switched methods. For future microbicide studies,
researchers need to prioritize these women and de-
velop a strategy of timely identification and providing
targeted care and counseling in dealing with women
Table 5. Baseline Predictors of Pregnancy in Cox Regression Models
Variable
Univariable Multivariable
HR (95% CI) P HR (95% CI) P
Site
Vulindlela Referent Referent
eThekwini 1.33 (0.76–2.34) .32 1.9 (0.97–4.03) .06
Age group (y)
18–24 Referent Referent
25–29 1.19 (0.62–2.31) .60 0.86 (0.43–1.72) .66
30–34 1.61 (0.74–3.48) .23 0.85 (0.34–2.12) .73
35 or older N/A
Type of contraception
DMPA Referent Referent
NET-EN 1.01 (0.29–3.59) .98 0.86 (0.24–3.11) .81
Oral 14.51 (7.58–27.78) .0001 15.91 (8.03–31.52) .0001
Marital status
Other Referent Referent
Married 1.1 (0.07–17.52) .95 1.54 (0.09–25.97) .77
Stable 3.57 (0.49–25.87) .20 3.59 (0.47–27.62) .22
Education
Primary school Referent Referent
High school 2.45 (0.34–17.74) .38 0.78 (0.11–5.83) .81
Tertiary 5.31 (0.65–43.18) .12 0.76 (0.08–6.92) .81
Number of previous live births
Previous live births (per one live birth increase) 0.71 (0.51–0.995) .047 0.95 (0.65–1.40) .81
Sex acts in past 30 d
Sex acts in last 30 d (per one act increase) 1.0 (0.98–1.03) .73 1.01 (0.98–1.05) .53
Condom use in past 30 d
Always Referent Referent
Inconsistent 1.29 (0.69–2.42) .42 2.05 (1.04–4.04) .04
HR, hazard ratio; CI, confidence interval; N/A, not applicable; DMPA, depot medroxyprogesterone acetate; NET-EN, norethisterone
enanthate; COC, combined oral contraceptive.
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who miss method replenishment dates and carefully
manage timing of switching to minimize pregnancies.
Exposure to tenofovir gel during pregnancy was
limited (median 14 days) and was not associated with
adverse outcomes in this trial. Most pregnancies
resulted in a full-term live birth. The three neonatal
deaths in this study were all in the placebo arm.
Additionally, no congenital anomalies were noted in
the 39 newborns that were delivered alive (both
preterm and full-term) and assessed in the early
postpartum period. Potential teratogenicity was min-
imized by optimizing frequency of pregnancy testing
using a highly sensitive testing assay and thus reduc-
ing the period of potential drug exposure. These
findings, albeit after very short exposure to the drug
and small sample size, are in keeping with those of the
Tenofovir Antiretroviral Pregnancy Registry, which
shows no evidence of higher rates of congenital
anomalies after systemic exposure in patients on
treatment.11 Furthermore, these findings are similar to
nonhuman studies in which there were no demonstra-
ble teratogenic effects up to 5 years after birth,
postexposure to chronic low-dose tenofovir in preg-
nancy.20 As a result of high HIV seroconversion rates
late in pregnancy, the safety of continuous gel use
throughout pregnancy needs to be evaluated further.
Product withdrawal resulting from pregnancy ac-
counted for only 1.6% of total person-time in
CAPRISA 004 with negligible statistical effect. It has
been shown that frequent pregnancy testing and using
highly sensitive pregnancy tests to diagnose preg-
nancy in HIV prevention trials may lead to many
false-positive or chemical pregnancies. Consequently,
women may be withdrawn from product for unnec-
essary prolonged periods of time, thus compromising
the power of the study.21 To overcome this limitation,
CAPRISA 004 successfully implemented a strategy to
minimize false-positive or chemical pregnancies. Ad-
ditionally, women continued study follow-up after a
pregnancy diagnosis until the pregnancy outcome
was established, allowing for timely product resump-
tion on pregnancy end.
The short duration of exposure to drug in utero
made it difficult to assess the effect of tenofovir gel on
pregnancy outcomes. In addition, high contraceptive
use rates and low pregnancy rates in CAPRISA 004
may have been the result of self-selection of women
not intending to fall pregnant into the study rather
than the effect of the contraceptive curriculum per se,
thus limiting generalizability of the results.
Strengths of this analysis include good contracep-
tive data; accurate and frequent testing for the preg-
nancy outcome; excellent retention; and a large
enough study sample size to yield an adequate num-
ber of pregnancy outcomes.
The comprehensive contraceptive curriculum, in-
cluding prespecified contraceptive and pregnancy-
related eligibility criteria developed for the CAPRISA
004 tenofovir gel trial, was an effective strategy for
enhancing contraceptive use and reducing pregnancy
rates in a microbicide trial. The pregnancy rate was
low and no safety concerns arose with the use of
tenofovir gel. As is the case in general use, injectable
methods were more effective in preventing pregnancy
than combined oral contraceptives. If the safety and
effectiveness of tenofovir gel are confirmed, contra-
ceptive use must be a prominent component of future
prevention trials. Additionally, safety studies on pro-
longed tenofovir gel use throughout pregnancy
should be prioritized because HIV prevention in
pregnancy is important to reduce maternal morbidity
and mortality, mother-to-child transmission, and in-
fant mortality.
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